$EVMN News

HC Wainwright & Co. Reiterates Buy on Evommune, Maintains $50 Price Target

Morgan Stanley Maintains Overweight on Evommune, Raises Price Target to $55

Evommune Q1 EPS $(0.64) Beats $(0.71) Estimate

Evommune Files Prospectus For Resale Of Up To 4,494,279 Shares Of Common Stock By Selling Stockholders

Evommune, Inc. (EVMN) Discusses Scientific Rationale and Pipeline Expansion for MRGPRX2 Antagonist in Migraine Prevention Transcript

RBC Capital Reiterates Outperform on Evommune, Maintains $48 Price Target

Clear Street Initiates Coverage of Evommune (EVMN) with Buy Recommendation

HC Wainwright & Co. Maintains Buy on Evommune, Lowers Price Target to $50

Clear Street Initiates Coverage On Evommune with Buy Rating, Announces Price Target of $53

Evommune shares are trading higher. The company reported Q4 financial results.

Evommune shares are trading higher. The company reported Q4 financial results.

Evommune Q4 EPS $(1.43) Misses $(0.74) Estimate

Evommune (EVMN) Price Target Increased by 37.87% to 55.08

Evommune CEO Luis Peña Reveals What’s Behind Company’s Post-IPO Success

Assessing Evommune (EVMN) Valuation After Strong Phase 2a Eczema Data And US$125.3m Placement

Evommune shares are trading higher. The company announced a $125 million private placement of 4,494,279 shares at $27.88.

Reported Earlier, Evommune Announces $125M Private Placement Selling 4,494,279 Common Shares At $27.88 Per Share To Institutional Investors

Evommune Announces $125 Million Private Placement

Evommune Stock Cools Off After Big Rally On Successful Eczema Trial

Evommune's EVO301 Phase 2a Data Drives 70% Stock Surge